On April 8, 2024, Seres Therapeutics, Inc announced that it has held its annual general meeting of shareholders on April 4, 2024, and declared voting results. Accordingly, a stockholder proposal on simple majority vote from Kenneth Steiner was approved by the shareholders of the Company.